1.Daruich A, Matet A, Dirani A, Bousquet E, Zhao M, Farman N, Jaisser F and Behar-Cohen F. Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis. Progress in retinal and eye research. 2015;48:82–118.
2.Loo RH, Scott IU, Flynn HW, Jr., Gass JD, Murray TG, Lewis ML, Rosenfeld PJ and Smiddy WE. Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy. Retina (Philadelphia, Pa). 2002;22:19–24.
3.Marmor MF. New hypotheses on the pathogenesis and treatment of serous retinal detachment. Graefe’s archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 1988;226:548–52.
4.Prunte C and Flammer J. [Circulatory disorders of the choroid in patients with central serious chorioretinopathy]. Klinische Monatsblatter fur Augenheilkunde. 1996;208:337–9.
5.Burumcek E, Mudun A, Karacorlu S and Arslan MO. Laser photocoagulation for persistent central serous retinopathy: results of long-term follow-up. Ophthalmology. 1997;104:616–22.
6.Nielsen JS and Jampol LM. Oral mifepristone for chronic central serous chorioretinopathy. Retina (Philadelphia, Pa). 2011;31:1928–36.
7.Pikkel J, Beiran I, Ophir A and Miller B. Acetazolamide for central serous retinopathy. Ophthalmology. 2002;109:1723–5.
8.Ruiz-Moreno JM, Lugo FL, Armada F, Silva R, Montero JA, Arevalo JF, Arias L and Gomez-Ulla F. Photodynamic therapy for chronic central serous chorioretinopathy. Acta ophthalmologica. 2010;88:371–6.
9.Torres-Soriano ME, García-Aguirre G, Kon-Jara V, Ustariz-Gonzáles O, Abraham-Marín M, Ober MD and Quiroz-Mercado H. A pilot study of intravitreal bevacizumab for the treatment of central serous chorioretinopathy (case reports). Graefe’s archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2008;246:1235–1239.
10.Artunay O, Yuzbasioglu E, Rasier R, Sengul A and Bahcecioglu H. Intravitreal bevacizumab in treatment of idiopathic persistent central serous chorioretinopathy: a prospective, controlled clinical study. Current eye research. 2010;35:91–8.
11.Huang WC, Chen WL, Tsai YY, Chiang CC and Lin JM. Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy. Eye (London, England). 2009;23:488–9.
12.Jung SH, Kim KA, Sohn SW and Yang SJ. Cytokine levels of the aqueous humour in central serous chorioretinopathy. Clinical & experimental optometry. 2014;97:264–9.
13.Kim GA, Rim TH, Lee SC, Byeon SH, Koh HJ, Kim SS and Lee CS. Clinical characteristics of responders to intravitreal bevacizumab in central serous chorioretinopathy patients. Eye (London, England). 2015;29:732–40; quiz 741.
14.Kim DY, Joe SG, Yang SJ, Lee JY, Kim JG and Yoon YH. The association between choroidal thickness variations and response to intravitreal bevacizumab in central serous chorioretinopathy. Korean journal of ophthalmology: KJO. 2015;29:160–7.
15.Shin KH, Kim JH, Cho SW, Lee TG, Kim CG and Kim JW. Efficacy of Intravitreal Bevacizumab for Recurrent Central Serous Chorioretinopathy in Patients Who Had Previously Responded Well to the Same Therapy. Journal of ocular pharmacology and therapeutics: the official journal of the Association for Ocular Pharmacology and Therapeutics. 2016;32:425–30.
16.Dohrmann J, Lommatzsch A, Spital G and Pauleikhoff D. [Pathogenesis of central serous chorioretinopathy: angiographic and electrophysiological studies]. Der Ophthalmologe: Zeitschrift der Deutschen Ophthalmologischen Gesellschaft. 2001;98:1069–73.
17.Yannuzzi LA, Slakter JS, Gross NE, Spaide RF, Costa D, Huang SJ, Klancnik JM, Jr. and Aizman A. Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina (Philadelphia, Pa). 2003;23:288–98.
18.Jirarattanasopa P, Ooto S, Tsujikawa A, Yamashiro K, Hangai M, Hirata M, Matsumoto A and Yoshimura N. Assessment of macular choroidal thickness by optical coherence tomography and angiographic changes in central serous chorioretinopathy. Ophthalmology. 2012;119:1666–78.